Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

[1]  F. Alesiani,et al.  Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study , 2014 .

[2]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[3]  E. Gorak,et al.  Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma , 2013, British journal of haematology.

[4]  D. Niederwieser,et al.  Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma , 2013, Journal of Cancer Research and Clinical Oncology.

[5]  B. Pégourié,et al.  Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. , 2012 .

[6]  D. Niederwieser,et al.  Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone , 2012, Journal of Cancer Research and Clinical Oncology.

[7]  K. Ramasamy,et al.  Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease , 2011, British journal of haematology.

[8]  H. Döhner,et al.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Barlogie,et al.  Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Dimopoulos,et al.  Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. , 2009, Leukemia research.

[11]  L. Tremmel,et al.  Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Dimopoulos,et al.  Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. , 2009, Clinical lymphoma & myeloma.

[13]  E. Terpos,et al.  Management of complications in multiple myeloma. , 2009, Seminars in hematology.

[14]  P. Sonneveld,et al.  Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. , 2008, Clinical lymphoma & myeloma.

[15]  E. Kastritis,et al.  Pathogenesis and treatment of renal failure in multiple myeloma , 2008, Leukemia.

[16]  R. Neuwirth,et al.  Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study , 2008, Leukemia.

[17]  M. Dimopoulos,et al.  Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens , 2007, Leukemia & lymphoma.

[18]  R. Greil,et al.  Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study. , 2007 .

[19]  J. Drach,et al.  Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma , 2007, Haematologica.

[20]  Joseph D Tariman,et al.  Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. , 2007, Blood.

[21]  G. Morgan,et al.  Bortezomib (Velcade™) in the Treatment of Multiple Myeloma , 2006, Therapeutics and clinical risk management.

[22]  D. Niederwieser,et al.  Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19) , 2006, Journal of Cancer Research and Clinical Oncology.

[23]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[24]  V. Gandhi.  Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. , 2002, Seminars in oncology.

[25]  D. Niederwieser,et al.  Bendamustine in the treatment of multiple myeloma: results and future perspectives. , 2002, Seminars in oncology.

[26]  R. Soutar,et al.  Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. , 1999, Blood reviews.

[27]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[28]  B. Barlogie,et al.  Renal failure in multiple myeloma. Pathogenesis and prognostic implications. , 1990, Archives of internal medicine.

[29]  B. Barlogie,et al.  Renal Failure in Multiple Myeloma , 1990 .

[30]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[31]  F. Alesiani,et al.  BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. , 2012 .

[32]  G. Morgan,et al.  Bortezomib ( Velcade TM ) in the treatment of multiple myeloma , 2006 .

[33]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[34]  M. Gordon.  Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .

[35]  H. Einsele,et al.  The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. , 2005, Haematologica.

[36]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[37]  A. Venditti,et al.  Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. , 2003, The hematology journal : the official journal of the European Haematology Association.

[38]  G. Spaeth.  The successful treatment of patients. , 1995, Ophthalmic surgery.